Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

In the Phase 3 DEFINE study, delayed-release dimethyl fumarate (DMF) 240 mg twice (BID) and three times daily (TID) significantly reduced the mean number of new or enlarging T2-hyperintense lesions and gadolinium-enhancing (Gd+) lesion activity at 2 years in patients (MRI cohort; n = 540) with relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Arnold, Douglas L., Gold, Ralf, Kappos, Ludwig, Bar-Or, Amit, Giovannoni, Gavin, Selmaj, Krzysztof, Yang, Minhua, Zhang, Ray, Stephan, Monica, Sheikh, Sarah I., Dawson, Katherine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155185/
https://www.ncbi.nlm.nih.gov/pubmed/24989666
http://dx.doi.org/10.1007/s00415-014-7412-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155185/
https://www.ncbi.nlm.nih.gov/pubmed/24989666
http://dx.doi.org/10.1007/s00415-014-7412-x

Ejemplares similares